Global Candidiasis Therapeutics

Candidiasis Therapeutics Comprehensive Study by Application (Multispecialty Hospitals, Cancer Research Institutes, Others), Drug (Polyene, Azole, Echinocandin, Other Types of Drugs), Route of Administration (Injection, Ointment, Oral), Distribution Channel (Hospitals, Clinics, Retail Pharmacies, Drug Stores), Anatomy (Oral Candidiasis, Vulvovaginal Candidiasis, Cutaneous Candidiasis, Invasive Candidiasis, Systemic Candidiasis) Players and Region - Global Market Outlook to 2030

Candidiasis Therapeutics Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Candidiasis Therapeutics
The candidiasis therapeutics market is expected to grow in the future due to the increase in the number of patients affected by candidiasis infection and an increase in the susceptible immune-compromised patient pool. Candidiasis, also known as common yeast infection, is an infection in the skin caused by candida. High adoption due to innovative drugs will help to boost the global candidiasis therapeutics market.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


Candidiasis Therapeutics is highly competitive, with several key players dominating the industry. The market players are focused on developing a variety of features and benefits to meet the needs. Thus, constantly introducing new innovation in processing to meet the changing needs and preferences of consumers. The companies are also planning strategic activities like partnerships, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Candidiasis Therapeutics market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Novartis International AG (Switzerland), Amgen Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), Pfizer (United States), Bayer AG (Germany), Merrion Pharmaceuticals Plc. (Ireland), Ablynx (Belgium), Genta Incorporated (United States), Galapagos NV (Belgium) and Catena Pharmaceuticals, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Medivir (Sweden) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Candidiasis Therapeutics market by , Application (Multispecialty Hospitals, Cancer Research Institutes and Others) and Region.



On the basis of geography, the market of Candidiasis Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug, the sub-segment i.e. Polyene will boost the Candidiasis Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route of Administration, the sub-segment i.e. Injection will boost the Candidiasis Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospitals will boost the Candidiasis Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Anatomy, the sub-segment i.e. Oral Candidiasis will boost the Candidiasis Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Consumer Inclination towards Maintaining Aesthetic Appearance

Market Growth Drivers:
Increase in the Susceptible Immune-compromised Patient Pool and Growing Awareness for Candidiasis Infection

Challenges:
Less R&D Activity in this Sector

Restraints:
Competition from Herbal Medicines and Alternate Therapies

Opportunities:
High Investment in Healthcare and Owing Awareness for Candidiasis Infection in Developing Markets

Market Leaders and their expansionary development strategies
In July 2023, Melinta Therapeutics has launched Rezzayo (rezafungin), which was approved by the FDA in March 2023 to treat patients candidemia and invasive candidiasis in adults with limited or no alternative treatment options. It is the first new treatment option approved for patients with candidemia and invasive candidiasis in over a decade.
In March 2023, GSK plc and SCYNEXIS, Inc. announced they have entered into an exclusive licence agreement for Brexafemme (ibrexafungerp tablets), a US FDA approved, first-in-class antifungal for the treatment of vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC (RVVC). This exclusive licence agreement gives GSK rights to commercialise Brexafemme for VVC and RVVC while continuing to develop ibrexafungerp, which is in phase III clinical trials for the potential treatment of invasive candidiasis (IC), a life-threatening fungal infection.


Key Target Audience
Candidiasis Therapeutics Manufacturers, Candidiasis Therapeutics Distributors/Traders/Wholesalers, Candidiasis Therapeutics Subcomponent Manufacturers, Industry Association and Downstream Vendors

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Multispecialty Hospitals
  • Cancer Research Institutes
  • Others
By Drug
  • Polyene
  • Azole
  • Echinocandin
  • Other Types of Drugs

By Route of Administration
  • Injection
  • Ointment
  • Oral

By Distribution Channel
  • Hospitals
  • Clinics
  • Retail Pharmacies
  • Drug Stores

By Anatomy
  • Oral Candidiasis
  • Vulvovaginal Candidiasis
  • Cutaneous Candidiasis
  • Invasive Candidiasis
  • Systemic Candidiasis

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in the Susceptible Immune-compromised Patient Pool
      • 3.2.2. Growing Awareness for Candidiasis Infection
    • 3.3. Market Challenges
      • 3.3.1. Less R&D Activity in this Sector
    • 3.4. Market Trends
      • 3.4.1. Increasing Consumer Inclination towards Maintaining Aesthetic Appearance
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Candidiasis Therapeutics, by Application, Drug, Route of Administration, Distribution Channel, Anatomy and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Candidiasis Therapeutics (Value)
      • 5.2.1. Global Candidiasis Therapeutics by: Application (Value)
        • 5.2.1.1. Multispecialty Hospitals
        • 5.2.1.2. Cancer Research Institutes
        • 5.2.1.3. Others
      • 5.2.2. Global Candidiasis Therapeutics by: Drug (Value)
        • 5.2.2.1. Polyene
        • 5.2.2.2. Azole
        • 5.2.2.3. Echinocandin
        • 5.2.2.4. Other Types of Drugs
      • 5.2.3. Global Candidiasis Therapeutics by: Route of Administration (Value)
        • 5.2.3.1. Injection
        • 5.2.3.2. Ointment
        • 5.2.3.3. Oral
      • 5.2.4. Global Candidiasis Therapeutics by: Distribution Channel (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Clinics
        • 5.2.4.3. Retail Pharmacies
        • 5.2.4.4. Drug Stores
      • 5.2.5. Global Candidiasis Therapeutics by: Anatomy (Value)
        • 5.2.5.1. Oral Candidiasis
        • 5.2.5.2. Vulvovaginal Candidiasis
        • 5.2.5.3. Cutaneous Candidiasis
        • 5.2.5.4. Invasive Candidiasis
        • 5.2.5.5. Systemic Candidiasis
      • 5.2.6. Global Candidiasis Therapeutics Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Candidiasis Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis International AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Amgen Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merrion Pharmaceuticals Plc. (Ireland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Ablynx (Belgium)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Genta Incorporated (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Galapagos NV (Belgium)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Catena Pharmaceuticals, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Candidiasis Therapeutics Sale, by Application, Drug, Route of Administration, Distribution Channel, Anatomy and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Candidiasis Therapeutics (Value)
      • 7.2.1. Global Candidiasis Therapeutics by: Application (Value)
        • 7.2.1.1. Multispecialty Hospitals
        • 7.2.1.2. Cancer Research Institutes
        • 7.2.1.3. Others
      • 7.2.2. Global Candidiasis Therapeutics by: Drug (Value)
        • 7.2.2.1. Polyene
        • 7.2.2.2. Azole
        • 7.2.2.3. Echinocandin
        • 7.2.2.4. Other Types of Drugs
      • 7.2.3. Global Candidiasis Therapeutics by: Route of Administration (Value)
        • 7.2.3.1. Injection
        • 7.2.3.2. Ointment
        • 7.2.3.3. Oral
      • 7.2.4. Global Candidiasis Therapeutics by: Distribution Channel (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Clinics
        • 7.2.4.3. Retail Pharmacies
        • 7.2.4.4. Drug Stores
      • 7.2.5. Global Candidiasis Therapeutics by: Anatomy (Value)
        • 7.2.5.1. Oral Candidiasis
        • 7.2.5.2. Vulvovaginal Candidiasis
        • 7.2.5.3. Cutaneous Candidiasis
        • 7.2.5.4. Invasive Candidiasis
        • 7.2.5.5. Systemic Candidiasis
      • 7.2.6. Global Candidiasis Therapeutics Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Candidiasis Therapeutics: by Application(USD Million)
  • Table 2. Candidiasis Therapeutics Multispecialty Hospitals , by Region USD Million (2018-2023)
  • Table 3. Candidiasis Therapeutics Cancer Research Institutes , by Region USD Million (2018-2023)
  • Table 4. Candidiasis Therapeutics Others , by Region USD Million (2018-2023)
  • Table 5. Candidiasis Therapeutics: by Drug(USD Million)
  • Table 6. Candidiasis Therapeutics Polyene , by Region USD Million (2018-2023)
  • Table 7. Candidiasis Therapeutics Azole , by Region USD Million (2018-2023)
  • Table 8. Candidiasis Therapeutics Echinocandin , by Region USD Million (2018-2023)
  • Table 9. Candidiasis Therapeutics Other Types of Drugs , by Region USD Million (2018-2023)
  • Table 10. Candidiasis Therapeutics: by Route of Administration(USD Million)
  • Table 11. Candidiasis Therapeutics Injection , by Region USD Million (2018-2023)
  • Table 12. Candidiasis Therapeutics Ointment , by Region USD Million (2018-2023)
  • Table 13. Candidiasis Therapeutics Oral , by Region USD Million (2018-2023)
  • Table 14. Candidiasis Therapeutics: by Distribution Channel(USD Million)
  • Table 15. Candidiasis Therapeutics Hospitals , by Region USD Million (2018-2023)
  • Table 16. Candidiasis Therapeutics Clinics , by Region USD Million (2018-2023)
  • Table 17. Candidiasis Therapeutics Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 18. Candidiasis Therapeutics Drug Stores , by Region USD Million (2018-2023)
  • Table 19. Candidiasis Therapeutics: by Anatomy(USD Million)
  • Table 20. Candidiasis Therapeutics Oral Candidiasis , by Region USD Million (2018-2023)
  • Table 21. Candidiasis Therapeutics Vulvovaginal Candidiasis , by Region USD Million (2018-2023)
  • Table 22. Candidiasis Therapeutics Cutaneous Candidiasis , by Region USD Million (2018-2023)
  • Table 23. Candidiasis Therapeutics Invasive Candidiasis , by Region USD Million (2018-2023)
  • Table 24. Candidiasis Therapeutics Systemic Candidiasis , by Region USD Million (2018-2023)
  • Table 25. South America Candidiasis Therapeutics, by Country USD Million (2018-2023)
  • Table 26. South America Candidiasis Therapeutics, by Application USD Million (2018-2023)
  • Table 27. South America Candidiasis Therapeutics, by Drug USD Million (2018-2023)
  • Table 28. South America Candidiasis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 29. South America Candidiasis Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 30. South America Candidiasis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 31. Brazil Candidiasis Therapeutics, by Application USD Million (2018-2023)
  • Table 32. Brazil Candidiasis Therapeutics, by Drug USD Million (2018-2023)
  • Table 33. Brazil Candidiasis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 34. Brazil Candidiasis Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 35. Brazil Candidiasis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 36. Argentina Candidiasis Therapeutics, by Application USD Million (2018-2023)
  • Table 37. Argentina Candidiasis Therapeutics, by Drug USD Million (2018-2023)
  • Table 38. Argentina Candidiasis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 39. Argentina Candidiasis Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 40. Argentina Candidiasis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 41. Rest of South America Candidiasis Therapeutics, by Application USD Million (2018-2023)
  • Table 42. Rest of South America Candidiasis Therapeutics, by Drug USD Million (2018-2023)
  • Table 43. Rest of South America Candidiasis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 44. Rest of South America Candidiasis Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 45. Rest of South America Candidiasis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 46. Asia Pacific Candidiasis Therapeutics, by Country USD Million (2018-2023)
  • Table 47. Asia Pacific Candidiasis Therapeutics, by Application USD Million (2018-2023)
  • Table 48. Asia Pacific Candidiasis Therapeutics, by Drug USD Million (2018-2023)
  • Table 49. Asia Pacific Candidiasis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 50. Asia Pacific Candidiasis Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 51. Asia Pacific Candidiasis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 52. China Candidiasis Therapeutics, by Application USD Million (2018-2023)
  • Table 53. China Candidiasis Therapeutics, by Drug USD Million (2018-2023)
  • Table 54. China Candidiasis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 55. China Candidiasis Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 56. China Candidiasis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 57. Japan Candidiasis Therapeutics, by Application USD Million (2018-2023)
  • Table 58. Japan Candidiasis Therapeutics, by Drug USD Million (2018-2023)
  • Table 59. Japan Candidiasis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 60. Japan Candidiasis Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 61. Japan Candidiasis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 62. India Candidiasis Therapeutics, by Application USD Million (2018-2023)
  • Table 63. India Candidiasis Therapeutics, by Drug USD Million (2018-2023)
  • Table 64. India Candidiasis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 65. India Candidiasis Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 66. India Candidiasis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 67. South Korea Candidiasis Therapeutics, by Application USD Million (2018-2023)
  • Table 68. South Korea Candidiasis Therapeutics, by Drug USD Million (2018-2023)
  • Table 69. South Korea Candidiasis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 70. South Korea Candidiasis Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 71. South Korea Candidiasis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 72. Taiwan Candidiasis Therapeutics, by Application USD Million (2018-2023)
  • Table 73. Taiwan Candidiasis Therapeutics, by Drug USD Million (2018-2023)
  • Table 74. Taiwan Candidiasis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 75. Taiwan Candidiasis Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 76. Taiwan Candidiasis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 77. Australia Candidiasis Therapeutics, by Application USD Million (2018-2023)
  • Table 78. Australia Candidiasis Therapeutics, by Drug USD Million (2018-2023)
  • Table 79. Australia Candidiasis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 80. Australia Candidiasis Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 81. Australia Candidiasis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 82. Rest of Asia-Pacific Candidiasis Therapeutics, by Application USD Million (2018-2023)
  • Table 83. Rest of Asia-Pacific Candidiasis Therapeutics, by Drug USD Million (2018-2023)
  • Table 84. Rest of Asia-Pacific Candidiasis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 85. Rest of Asia-Pacific Candidiasis Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 86. Rest of Asia-Pacific Candidiasis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 87. Europe Candidiasis Therapeutics, by Country USD Million (2018-2023)
  • Table 88. Europe Candidiasis Therapeutics, by Application USD Million (2018-2023)
  • Table 89. Europe Candidiasis Therapeutics, by Drug USD Million (2018-2023)
  • Table 90. Europe Candidiasis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 91. Europe Candidiasis Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 92. Europe Candidiasis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 93. Germany Candidiasis Therapeutics, by Application USD Million (2018-2023)
  • Table 94. Germany Candidiasis Therapeutics, by Drug USD Million (2018-2023)
  • Table 95. Germany Candidiasis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 96. Germany Candidiasis Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 97. Germany Candidiasis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 98. France Candidiasis Therapeutics, by Application USD Million (2018-2023)
  • Table 99. France Candidiasis Therapeutics, by Drug USD Million (2018-2023)
  • Table 100. France Candidiasis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 101. France Candidiasis Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 102. France Candidiasis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 103. Italy Candidiasis Therapeutics, by Application USD Million (2018-2023)
  • Table 104. Italy Candidiasis Therapeutics, by Drug USD Million (2018-2023)
  • Table 105. Italy Candidiasis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 106. Italy Candidiasis Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 107. Italy Candidiasis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 108. United Kingdom Candidiasis Therapeutics, by Application USD Million (2018-2023)
  • Table 109. United Kingdom Candidiasis Therapeutics, by Drug USD Million (2018-2023)
  • Table 110. United Kingdom Candidiasis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 111. United Kingdom Candidiasis Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 112. United Kingdom Candidiasis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 113. Netherlands Candidiasis Therapeutics, by Application USD Million (2018-2023)
  • Table 114. Netherlands Candidiasis Therapeutics, by Drug USD Million (2018-2023)
  • Table 115. Netherlands Candidiasis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 116. Netherlands Candidiasis Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 117. Netherlands Candidiasis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 118. Rest of Europe Candidiasis Therapeutics, by Application USD Million (2018-2023)
  • Table 119. Rest of Europe Candidiasis Therapeutics, by Drug USD Million (2018-2023)
  • Table 120. Rest of Europe Candidiasis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 121. Rest of Europe Candidiasis Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 122. Rest of Europe Candidiasis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 123. MEA Candidiasis Therapeutics, by Country USD Million (2018-2023)
  • Table 124. MEA Candidiasis Therapeutics, by Application USD Million (2018-2023)
  • Table 125. MEA Candidiasis Therapeutics, by Drug USD Million (2018-2023)
  • Table 126. MEA Candidiasis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 127. MEA Candidiasis Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 128. MEA Candidiasis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 129. Middle East Candidiasis Therapeutics, by Application USD Million (2018-2023)
  • Table 130. Middle East Candidiasis Therapeutics, by Drug USD Million (2018-2023)
  • Table 131. Middle East Candidiasis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 132. Middle East Candidiasis Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 133. Middle East Candidiasis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 134. Africa Candidiasis Therapeutics, by Application USD Million (2018-2023)
  • Table 135. Africa Candidiasis Therapeutics, by Drug USD Million (2018-2023)
  • Table 136. Africa Candidiasis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 137. Africa Candidiasis Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 138. Africa Candidiasis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 139. North America Candidiasis Therapeutics, by Country USD Million (2018-2023)
  • Table 140. North America Candidiasis Therapeutics, by Application USD Million (2018-2023)
  • Table 141. North America Candidiasis Therapeutics, by Drug USD Million (2018-2023)
  • Table 142. North America Candidiasis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 143. North America Candidiasis Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 144. North America Candidiasis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 145. United States Candidiasis Therapeutics, by Application USD Million (2018-2023)
  • Table 146. United States Candidiasis Therapeutics, by Drug USD Million (2018-2023)
  • Table 147. United States Candidiasis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 148. United States Candidiasis Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 149. United States Candidiasis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 150. Canada Candidiasis Therapeutics, by Application USD Million (2018-2023)
  • Table 151. Canada Candidiasis Therapeutics, by Drug USD Million (2018-2023)
  • Table 152. Canada Candidiasis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 153. Canada Candidiasis Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 154. Canada Candidiasis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 155. Mexico Candidiasis Therapeutics, by Application USD Million (2018-2023)
  • Table 156. Mexico Candidiasis Therapeutics, by Drug USD Million (2018-2023)
  • Table 157. Mexico Candidiasis Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 158. Mexico Candidiasis Therapeutics, by Distribution Channel USD Million (2018-2023)
  • Table 159. Mexico Candidiasis Therapeutics, by Anatomy USD Million (2018-2023)
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Candidiasis Therapeutics: by Application(USD Million)
  • Table 171. Candidiasis Therapeutics Multispecialty Hospitals , by Region USD Million (2025-2030)
  • Table 172. Candidiasis Therapeutics Cancer Research Institutes , by Region USD Million (2025-2030)
  • Table 173. Candidiasis Therapeutics Others , by Region USD Million (2025-2030)
  • Table 174. Candidiasis Therapeutics: by Drug(USD Million)
  • Table 175. Candidiasis Therapeutics Polyene , by Region USD Million (2025-2030)
  • Table 176. Candidiasis Therapeutics Azole , by Region USD Million (2025-2030)
  • Table 177. Candidiasis Therapeutics Echinocandin , by Region USD Million (2025-2030)
  • Table 178. Candidiasis Therapeutics Other Types of Drugs , by Region USD Million (2025-2030)
  • Table 179. Candidiasis Therapeutics: by Route of Administration(USD Million)
  • Table 180. Candidiasis Therapeutics Injection , by Region USD Million (2025-2030)
  • Table 181. Candidiasis Therapeutics Ointment , by Region USD Million (2025-2030)
  • Table 182. Candidiasis Therapeutics Oral , by Region USD Million (2025-2030)
  • Table 183. Candidiasis Therapeutics: by Distribution Channel(USD Million)
  • Table 184. Candidiasis Therapeutics Hospitals , by Region USD Million (2025-2030)
  • Table 185. Candidiasis Therapeutics Clinics , by Region USD Million (2025-2030)
  • Table 186. Candidiasis Therapeutics Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 187. Candidiasis Therapeutics Drug Stores , by Region USD Million (2025-2030)
  • Table 188. Candidiasis Therapeutics: by Anatomy(USD Million)
  • Table 189. Candidiasis Therapeutics Oral Candidiasis , by Region USD Million (2025-2030)
  • Table 190. Candidiasis Therapeutics Vulvovaginal Candidiasis , by Region USD Million (2025-2030)
  • Table 191. Candidiasis Therapeutics Cutaneous Candidiasis , by Region USD Million (2025-2030)
  • Table 192. Candidiasis Therapeutics Invasive Candidiasis , by Region USD Million (2025-2030)
  • Table 193. Candidiasis Therapeutics Systemic Candidiasis , by Region USD Million (2025-2030)
  • Table 194. South America Candidiasis Therapeutics, by Country USD Million (2025-2030)
  • Table 195. South America Candidiasis Therapeutics, by Application USD Million (2025-2030)
  • Table 196. South America Candidiasis Therapeutics, by Drug USD Million (2025-2030)
  • Table 197. South America Candidiasis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 198. South America Candidiasis Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 199. South America Candidiasis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 200. Brazil Candidiasis Therapeutics, by Application USD Million (2025-2030)
  • Table 201. Brazil Candidiasis Therapeutics, by Drug USD Million (2025-2030)
  • Table 202. Brazil Candidiasis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 203. Brazil Candidiasis Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 204. Brazil Candidiasis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 205. Argentina Candidiasis Therapeutics, by Application USD Million (2025-2030)
  • Table 206. Argentina Candidiasis Therapeutics, by Drug USD Million (2025-2030)
  • Table 207. Argentina Candidiasis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 208. Argentina Candidiasis Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 209. Argentina Candidiasis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 210. Rest of South America Candidiasis Therapeutics, by Application USD Million (2025-2030)
  • Table 211. Rest of South America Candidiasis Therapeutics, by Drug USD Million (2025-2030)
  • Table 212. Rest of South America Candidiasis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 213. Rest of South America Candidiasis Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 214. Rest of South America Candidiasis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 215. Asia Pacific Candidiasis Therapeutics, by Country USD Million (2025-2030)
  • Table 216. Asia Pacific Candidiasis Therapeutics, by Application USD Million (2025-2030)
  • Table 217. Asia Pacific Candidiasis Therapeutics, by Drug USD Million (2025-2030)
  • Table 218. Asia Pacific Candidiasis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 219. Asia Pacific Candidiasis Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 220. Asia Pacific Candidiasis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 221. China Candidiasis Therapeutics, by Application USD Million (2025-2030)
  • Table 222. China Candidiasis Therapeutics, by Drug USD Million (2025-2030)
  • Table 223. China Candidiasis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 224. China Candidiasis Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 225. China Candidiasis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 226. Japan Candidiasis Therapeutics, by Application USD Million (2025-2030)
  • Table 227. Japan Candidiasis Therapeutics, by Drug USD Million (2025-2030)
  • Table 228. Japan Candidiasis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 229. Japan Candidiasis Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 230. Japan Candidiasis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 231. India Candidiasis Therapeutics, by Application USD Million (2025-2030)
  • Table 232. India Candidiasis Therapeutics, by Drug USD Million (2025-2030)
  • Table 233. India Candidiasis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 234. India Candidiasis Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 235. India Candidiasis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 236. South Korea Candidiasis Therapeutics, by Application USD Million (2025-2030)
  • Table 237. South Korea Candidiasis Therapeutics, by Drug USD Million (2025-2030)
  • Table 238. South Korea Candidiasis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 239. South Korea Candidiasis Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 240. South Korea Candidiasis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 241. Taiwan Candidiasis Therapeutics, by Application USD Million (2025-2030)
  • Table 242. Taiwan Candidiasis Therapeutics, by Drug USD Million (2025-2030)
  • Table 243. Taiwan Candidiasis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 244. Taiwan Candidiasis Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 245. Taiwan Candidiasis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 246. Australia Candidiasis Therapeutics, by Application USD Million (2025-2030)
  • Table 247. Australia Candidiasis Therapeutics, by Drug USD Million (2025-2030)
  • Table 248. Australia Candidiasis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 249. Australia Candidiasis Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 250. Australia Candidiasis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 251. Rest of Asia-Pacific Candidiasis Therapeutics, by Application USD Million (2025-2030)
  • Table 252. Rest of Asia-Pacific Candidiasis Therapeutics, by Drug USD Million (2025-2030)
  • Table 253. Rest of Asia-Pacific Candidiasis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 254. Rest of Asia-Pacific Candidiasis Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 255. Rest of Asia-Pacific Candidiasis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 256. Europe Candidiasis Therapeutics, by Country USD Million (2025-2030)
  • Table 257. Europe Candidiasis Therapeutics, by Application USD Million (2025-2030)
  • Table 258. Europe Candidiasis Therapeutics, by Drug USD Million (2025-2030)
  • Table 259. Europe Candidiasis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 260. Europe Candidiasis Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 261. Europe Candidiasis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 262. Germany Candidiasis Therapeutics, by Application USD Million (2025-2030)
  • Table 263. Germany Candidiasis Therapeutics, by Drug USD Million (2025-2030)
  • Table 264. Germany Candidiasis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 265. Germany Candidiasis Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 266. Germany Candidiasis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 267. France Candidiasis Therapeutics, by Application USD Million (2025-2030)
  • Table 268. France Candidiasis Therapeutics, by Drug USD Million (2025-2030)
  • Table 269. France Candidiasis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 270. France Candidiasis Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 271. France Candidiasis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 272. Italy Candidiasis Therapeutics, by Application USD Million (2025-2030)
  • Table 273. Italy Candidiasis Therapeutics, by Drug USD Million (2025-2030)
  • Table 274. Italy Candidiasis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 275. Italy Candidiasis Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 276. Italy Candidiasis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 277. United Kingdom Candidiasis Therapeutics, by Application USD Million (2025-2030)
  • Table 278. United Kingdom Candidiasis Therapeutics, by Drug USD Million (2025-2030)
  • Table 279. United Kingdom Candidiasis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 280. United Kingdom Candidiasis Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 281. United Kingdom Candidiasis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 282. Netherlands Candidiasis Therapeutics, by Application USD Million (2025-2030)
  • Table 283. Netherlands Candidiasis Therapeutics, by Drug USD Million (2025-2030)
  • Table 284. Netherlands Candidiasis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 285. Netherlands Candidiasis Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 286. Netherlands Candidiasis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 287. Rest of Europe Candidiasis Therapeutics, by Application USD Million (2025-2030)
  • Table 288. Rest of Europe Candidiasis Therapeutics, by Drug USD Million (2025-2030)
  • Table 289. Rest of Europe Candidiasis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 290. Rest of Europe Candidiasis Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 291. Rest of Europe Candidiasis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 292. MEA Candidiasis Therapeutics, by Country USD Million (2025-2030)
  • Table 293. MEA Candidiasis Therapeutics, by Application USD Million (2025-2030)
  • Table 294. MEA Candidiasis Therapeutics, by Drug USD Million (2025-2030)
  • Table 295. MEA Candidiasis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 296. MEA Candidiasis Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 297. MEA Candidiasis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 298. Middle East Candidiasis Therapeutics, by Application USD Million (2025-2030)
  • Table 299. Middle East Candidiasis Therapeutics, by Drug USD Million (2025-2030)
  • Table 300. Middle East Candidiasis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 301. Middle East Candidiasis Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 302. Middle East Candidiasis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 303. Africa Candidiasis Therapeutics, by Application USD Million (2025-2030)
  • Table 304. Africa Candidiasis Therapeutics, by Drug USD Million (2025-2030)
  • Table 305. Africa Candidiasis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 306. Africa Candidiasis Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 307. Africa Candidiasis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 308. North America Candidiasis Therapeutics, by Country USD Million (2025-2030)
  • Table 309. North America Candidiasis Therapeutics, by Application USD Million (2025-2030)
  • Table 310. North America Candidiasis Therapeutics, by Drug USD Million (2025-2030)
  • Table 311. North America Candidiasis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 312. North America Candidiasis Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 313. North America Candidiasis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 314. United States Candidiasis Therapeutics, by Application USD Million (2025-2030)
  • Table 315. United States Candidiasis Therapeutics, by Drug USD Million (2025-2030)
  • Table 316. United States Candidiasis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 317. United States Candidiasis Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 318. United States Candidiasis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 319. Canada Candidiasis Therapeutics, by Application USD Million (2025-2030)
  • Table 320. Canada Candidiasis Therapeutics, by Drug USD Million (2025-2030)
  • Table 321. Canada Candidiasis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 322. Canada Candidiasis Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 323. Canada Candidiasis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 324. Mexico Candidiasis Therapeutics, by Application USD Million (2025-2030)
  • Table 325. Mexico Candidiasis Therapeutics, by Drug USD Million (2025-2030)
  • Table 326. Mexico Candidiasis Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 327. Mexico Candidiasis Therapeutics, by Distribution Channel USD Million (2025-2030)
  • Table 328. Mexico Candidiasis Therapeutics, by Anatomy USD Million (2025-2030)
  • Table 329. Research Programs/Design for This Report
  • Table 330. Key Data Information from Secondary Sources
  • Table 331. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Candidiasis Therapeutics: by Application USD Million (2018-2023)
  • Figure 5. Global Candidiasis Therapeutics: by Drug USD Million (2018-2023)
  • Figure 6. Global Candidiasis Therapeutics: by Route of Administration USD Million (2018-2023)
  • Figure 7. Global Candidiasis Therapeutics: by Distribution Channel USD Million (2018-2023)
  • Figure 8. Global Candidiasis Therapeutics: by Anatomy USD Million (2018-2023)
  • Figure 9. South America Candidiasis Therapeutics Share (%), by Country
  • Figure 10. Asia Pacific Candidiasis Therapeutics Share (%), by Country
  • Figure 11. Europe Candidiasis Therapeutics Share (%), by Country
  • Figure 12. MEA Candidiasis Therapeutics Share (%), by Country
  • Figure 13. North America Candidiasis Therapeutics Share (%), by Country
  • Figure 14. Global Candidiasis Therapeutics share by Players 2023 (%)
  • Figure 15. Global Candidiasis Therapeutics share by Players (Top 3) 2023(%)
  • Figure 16. Global Candidiasis Therapeutics share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Novartis International AG (Switzerland) Revenue: by Geography 2023
  • Figure 20. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Amgen Inc. (United States) Revenue: by Geography 2023
  • Figure 22. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2023
  • Figure 24. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 25. Pfizer (United States) Revenue: by Geography 2023
  • Figure 26. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 28. Merrion Pharmaceuticals Plc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 29. Merrion Pharmaceuticals Plc. (Ireland) Revenue: by Geography 2023
  • Figure 30. Ablynx (Belgium) Revenue, Net Income and Gross profit
  • Figure 31. Ablynx (Belgium) Revenue: by Geography 2023
  • Figure 32. Genta Incorporated (United States) Revenue, Net Income and Gross profit
  • Figure 33. Genta Incorporated (United States) Revenue: by Geography 2023
  • Figure 34. Galapagos NV (Belgium) Revenue, Net Income and Gross profit
  • Figure 35. Galapagos NV (Belgium) Revenue: by Geography 2023
  • Figure 36. Catena Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Catena Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 38. Global Candidiasis Therapeutics: by Application USD Million (2025-2030)
  • Figure 39. Global Candidiasis Therapeutics: by Drug USD Million (2025-2030)
  • Figure 40. Global Candidiasis Therapeutics: by Route of Administration USD Million (2025-2030)
  • Figure 41. Global Candidiasis Therapeutics: by Distribution Channel USD Million (2025-2030)
  • Figure 42. Global Candidiasis Therapeutics: by Anatomy USD Million (2025-2030)
  • Figure 43. South America Candidiasis Therapeutics Share (%), by Country
  • Figure 44. Asia Pacific Candidiasis Therapeutics Share (%), by Country
  • Figure 45. Europe Candidiasis Therapeutics Share (%), by Country
  • Figure 46. MEA Candidiasis Therapeutics Share (%), by Country
  • Figure 47. North America Candidiasis Therapeutics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Novartis International AG (Switzerland)
  • Amgen Inc. (United States)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Pfizer (United States)
  • Bayer AG (Germany)
  • Merrion Pharmaceuticals Plc. (Ireland)
  • Ablynx (Belgium)
  • Genta Incorporated (United States)
  • Galapagos NV (Belgium)
  • Catena Pharmaceuticals, Inc. (United States)
Additional players considered in the study are as follows:
Medivir (Sweden) , Others
Select User Access Type

Key Highlights of Report


Jan 2024 229 Pages 90 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Candidiasis Therapeutics Quantitative research analysis
Global Candidiasis Therapeutics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Novartis International AG (Switzerland), Amgen Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), Pfizer (United States), Bayer AG (Germany), Merrion Pharmaceuticals Plc. (Ireland), Ablynx (Belgium), Genta Incorporated (United States), Galapagos NV (Belgium) and Catena Pharmaceuticals, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Consumer Inclination towards Maintaining Aesthetic Appearance" is seen as one of major influencing trends for Candidiasis Therapeutics Market during projected period 2023-2030.
The Candidiasis Therapeutics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Candidiasis Therapeutics Report?

Have a Query? Click Here

Other Related Reports

Friedreich Ataxia Drug Comprehensive Study by Type (Amitriptyline or Gabapentin, Muscle Relaxants, Antidepressants), Application (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacies,...
$ 3650
Hyperthermia Treatment for Cancer Comprehensive Study by Application (Head and neck, Brain, Lung, Endometrial, Breast, Bladder, Others), Technology (Ultrasound, Electromagnetic, Microwaves, Infrared)...
$ 3650
Huntingtons Disease Therapeutics Comprehensive Study by Application (Health Care Centres, Hospitals), Distribution Channel (Online, Hospital Pharmacies), Medication Type (Antidopaminergics, Anticonvu...
$ 3450
Ebola Virus Vaccine Comprehensive Study by Type (Live-attenuated Vaccines, Inactivated Vaccines, Others), Application (Hospitals and Clinics, Charity Organization), Diagnostic Tests (ELISA, Antigen-c...
$ 3750
Chickenpox Vaccine Comprehensive Study by Type (Monovalent Vaccine, Combination Vaccine), Application (Hospitals, Clinics, Laboratories), End User (Children, Adults) Players and Region - Global Marke...
$ 3500
Addiction Treatment Comprehensive Study by Type (Alcohol Addiction Treatment, Tobacco/Nicotine Addiction Treatment, Opioid Addiction Treatment, Other Substance Addiction Treatment), Drug Type (Buprop...
$ 3750